Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (the "Company") on April 25, 2018. The Company is incorporated in New Jersey and is designated as an emerging growth company. The report details significant changes to the Company's executive leadership and board structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On April 25, 2018, the Board of Directors executed the following personnel changes:
- Termination: Dr. Raymond F. Akers was terminated from his positions as Executive Chairman of the Board, Chief Scientific Director, and Secretary. He remains a member of the Board of Directors.
- Appointments: Richard Carlyle Tarbox III, a current director, was appointed as interim Non-Executive Chairman of the Board and Secretary. These appointments became effective immediately on April 25, 2018.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors. The primary contingency noted is the interim nature of Mr. Tarbox's appointment as Chairman, which will last until a successor is appointed in accordance with the Company's amended by-laws.
Investor Verification Checklist
- Verify the terms of Dr. Akers' separation agreement and any potential severance or litigation risks.
- Confirm the timeline and process for appointing a permanent successor to the Chairman role.
- Review the Company's amended Restated By-laws regarding the appointment of directors and officers.
- Assess the impact of the leadership transition on the Company's scientific strategy and ongoing operations.